LEADER 04530nam 2201189z- 450 001 9910580214803321 005 20231214133038.0 035 $a(CKB)5690000000011939 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87528 035 $a(EXLCZ)995690000000011939 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCrosstalk between Depression, Anxiety, and Dementia: Comorbidity in Behavioral Neurology and Neuropsychiatry 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (266 p.) 311 $a3-0365-4001-6 311 $a3-0365-4002-4 330 $aThis Special Issue highlights the most recent research on depression, anxiety and dementia, with attention to comorbidity in a range of diseases. The symptoms of depression, anxiety and dementia are the most common comorbid manifestations present in patients suffering from neurodegenerative and psychiatric diseases. Together, these illnesses constitute an extremely complex and challenging research field due to their inherent multifactorial causative factors, heterogeneous pathogenesis, and mental and behavioral manifestations. This Special Issue covers laboratory, clinical and statistical studies on the crosstalk between depression, anxiety, dementia, Alzheimer?s disease, multiple sclerosis, schizophrenia, diabetes mellitus, Down?s syndrome, and/or compulsive disorders. It contains contributions from 71 authors, has been reviewed by 25 referees, and edited by three academic editors and one managing editor. 517 $aCrosstalk between Depression, Anxiety, and Dementia 606 $aMedicine$2bicssc 606 $aClinical & internal medicine$2bicssc 610 $adementia 610 $abehavioral and psychological symptoms of dementia 610 $asystematic review 610 $ameta-analysis 610 $aanimal-assisted intervention 610 $apet-robot intervention 610 $aG protein-coupled receptors 610 $aGPR120 610 $aFFAR4 610 $aschizophrenia 610 $apolyunsaturated fatty acids 610 $along-chain fatty acids 610 $aomega-3 610 $anutritional psychiatry 610 $aAlzheimer?s disease 610 $apsychiatric disease 610 $adepression 610 $aanxiety 610 $aDown?s syndrome 610 $ainositol 610 $anutraceutical 610 $ainsulin signaling 610 $aantioxidant 610 $aaging 610 $apsilocybin 610 $aclinical trials 610 $aoxidative stress 610 $aredox 610 $amultiple sclerosis 610 $abiomarker 610 $aneurodegenerative disease 610 $apersonalized medicine 610 $amajor depressive disorder 610 $alongitudinal study 610 $aLC-MS/MS 610 $aplasma protein biomarker 610 $adrug response monitoring 610 $amultiple reaction monitoring 610 $adiabetes mellitus 610 $atype 2 610 $adyslipidemias 610 $ahypertension 610 $apost-stroke depression 610 $adisability level 610 $amortality 610 $alate-life depression 610 $aneuroimaging 610 $aresting-state functional magnetic resonance imaging 610 $adefault mode network 610 $aexecutive control network 610 $asalience network 610 $ahealthy life expectancy (HALE) 610 $amorbidity/mortality paradox 610 $acognition 610 $asystolic blood pressure 610 $acerebral blood flow 610 $aarterial properties 610 $aangiogenesis 610 $agender medicine 610 $aneurodegenerative disorders 610 $akisspeptin 610 $alocomotion 610 $aKiss1 receptor 610 $aHPA axis 610 $aHPG axis 610 $anucleus accumbens 610 $astroke 610 $alipid 610 $adiabetes 615 7$aMedicine 615 7$aClinical & internal medicine 700 $aTanaka$b Masaru$4edt$01318502 702 $aTanaka$b Masaru$4oth 906 $aBOOK 912 $a9910580214803321 996 $aCrosstalk between Depression, Anxiety, and Dementia: Comorbidity in Behavioral Neurology and Neuropsychiatry$93033337 997 $aUNINA